Menu Search
Equities

VentriPoint Diagnostics Ltd

5V7:BER

VentriPoint Diagnostics Ltd

Actions
  • Price (EUR)0.094
  • Today's Change-0.002 / -2.08%
  • Shares traded--
  • 1 Year change-2.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024 07:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

  • Revenue in CAD (TTM)72.07k
  • Net income in CAD-5.02m
  • Incorporated2007
  • Employees--
  • Location
    VentriPoint Diagnostics Ltd18 Hook Ave, Unit 101TORONTO M6P 1T4CanadaCAN
  • Phone+1 (416) 848-4156
  • Fax+1 (416) 848-0709
  • Websitehttps://www.ventripoint.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.